ALternate Site Cardiac ReSYNChronization (ALSYNC) Study

Exclusion Criteria

• •Patients having contraindications to Vitamin K antagonist therapy
• •Patients contraindicated for \< 100 micrograms beclomethasone dipropionate
• •Patients unable to tolerate an urgent thoracotomy
• •Documented (previous) ischemic or hemorrhagic stroke
• •Patients with known previous atrial septal defect closure, or history of mural thrombus that has not been resolved
• •Patients with documented atrial fibrillation AND increased stroke risk as determined by the Congestive Heart Failure, Hypertension, Age(2), Diabetes, Stroke(2), Vascular disease, Age, and Sex Category (CHA2DS2-VASc) Score of equal to or greater than 5
• •Patients with unstable angina pectoris or who have had an acute myocardial infarct within the past 30 days
• •Patients with known atrial septum defect (ASD) and/or left superior vena cava
• •Patient with known internal carotid artery stenosis of greater than 50%
• •Patients diagnosed with peripheral artery disease that are expected to undergo stenting within the next three months
• •Patients who have had a Coronary artery bypass graft or stent within the past three months
• •Patients with history of mitral or aortic valve repair or replacement
• •Post heart transplant patients (patients waiting for heart transplant are allowed in the study)
• •Patients currently undergoing dialysis treatment
• •Patients with ongoing chemotherapy and radiation therapy that may have an effect on cardiac function
• •Patients with ongoing Adverse Events from a previous Left Ventricle lead implant attempt
• •Patients enrolled in any concurrent drug and/or device study that may confound the results of this study
• •Patients who are not expected to survive more than twelve months